In vitro diagnostics (IVD) are diagnostic tests practiced in an artificial environment. The overall revenue of the Asia-Pacific IVD market accounted for about $10.7 billion in 2014, and is estimated to reach $15.3 billion by 2020, registering a CAGR of 6.5% over the forecast period. Considerable increase in the number of chronic and infectious diseases, growing awareness towards healthcare solutions and technological advancements in healthcare industry largely supplement the growth of this market. However, stringent regulatory policies and reimbursements issues in few countries limit the growth of this market. The rising demand for technologically advanced diagnostic devices, rise in GDP and per capita income and rise in disposable incomes facilitate a huge potential for the IVD market in the Asia-Pacific region.
The Asia-Pacific IVD market is segmented based on technique, product type, usability, application, end user and country. Based on technique, the market is segmented into immunoassays, clinical chemistry, point-of-care, molecular diagnostics, hematology, coagulation, microbiology and other clinical techniques. Point-of-care is the highest revenue-generating segment in the overall IVD techniques market. However, the molecular diagnostics is the fastest growing technique in the overall IVD techniques market due to its ability to accurately detect the primary cause of the disease.
Based on product type, the market is segmented into instruments, reagents, data management systems and services. Instruments segment holds the highest market share in the Asia-Pacific IVD market followed by rapidly growing reagents segment. Reagents are largely used in various equipment and play a key role in the overall diagnosis process. The usability segment is classified as disposable and reusable IVD devices. Doctors and clinicians largely prefer disposable devices to avoid infections; generating larger revenue in comparison to reusable devices. The application segment is categorized into infectious diseases diabetes, cancer/oncology, cardiology, autoimmune diseases, nephrology, drug testing, HIV/AIDS and others. Infectious diseases was the highest revenue-generating segment in 2014 and would continue to maintain its position throughout 2020, due to the rise in incidences of infectious diseases.
Hospitals and laboratories, academics, point-of-care testing and others form the end users segment in the Asia-Pacific IVD market. Hospitals and laboratories generate the highest revenue, followed by point-of-care. A significant rise in the number of hospitals and laboratories across the Asia-Pacific region along with increased awareness about developments in healthcare largely contribute to the growth of this segment.
Based on country, the Asia-Pacific IVD market is segmented into India, China, Japan, Australia, South Korea and rest of the Asia-Pacific. Currently, China leads the Asia-Pacific IVD market, owing to the high demand for testing in outpatient clinics, huge population base and rising medical insurance services by the Chinese government. However, Australia and South Korea hold the significant market share due to the well-supported reimbursement facilities and well-regulated IVD devices, which comes under the regulation of medical devices.
Key companies profiled in this market include Danaher Corporation, Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Alere Inc., Affymetrix Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, Vela Diagnostics and others. Product launch and technological advancements are the few strategies adopted by the key players of IVD market. The companies are currently focusing on innovative technologies such as automated and point-of-care IVD devices.
KEY BENEFITS:
IN VITRO DIAGNOSTICS MARKET KEY SEGMENTS:
Asia-Pacific IVD market is segmented into applications, technology, product type, usability, end user, and geography.
By Techniques
By Product Type
By Usability
By Applications
By End-User
By Countries
Chapter 1 INTRODUCTION
1.1 Report Description
1.2 Reason for doing the study
1.3 Key Take Away
1.4 Key Market Segments
1.5 Research Methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.5.3 Analyst tools and models
Chapter 2 EXECUTIVE SUMMARY
Chapter 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key Intelligence
3.2.1 Impact analysis
3.2.2 Market attractiveness analysis
3.2.3 Key Market Strategies
3.3 Governance Act and Remuneration
3.3.1 Regulations in China
3.3.2 Regulations in India
3.3.3 Regulations in Japan and Australia
3.4 Strategic Management Insights
3.4.1 Value Chain Analysis
3.4.1.1 Primary Activity
3.4.1.2 Supportive Activity
3.4.2 Porter Five Forces Analysis
3.4.2.1 Brand loyalty leads to moderate bargaining power of supplier
3.4.2.2 Varying product differentiation would lead to moderate bargaining power of buyers
3.4.2.3 Low threat from new entrants due to high entry barriers
3.4.2.4 Less intersegment substitution leads to lower threat Of substitute
3.4.2.5 Moderate competitive rivalry
3.5 Research & Analysis
3.5.1 Clinical Trials of research studies conducted for IVD market
3.6 Market Share Analysis of Asia-Pacific IVD Market (2014)
3.7 Significant Progressions in IVD technologies
3.7.1 Total Laboratory Automation (TLA)
3.7.2 Evolving markets in digital pathology
3.7.3 Omics and Genetics tests in IVD
3.7.4 Point-of-Care testing
3.7.5 Emerging technologies diagnostics and influence on IVD
3.8 Market Dynamics
3.8.1 Drivers
3.8.1.1 Increasing incidences of diseases
3.8.1.2 Technological advancements
3.8.1.3 Focus on prevention and diagnosis
3.8.1.4 Increasing healthcare expenditure
3.8.1.5 Upsurge of companion diagnostics
3.8.2 Restraints
3.8.2.1 Reimbursement issues
3.8.2.2 Stringent regulatory policies
3.8.2.3 UnAffordability of latest sophisticated tests
3.8.3 Opportunities
3.8.3.1 Potential outsourcing Opportunities in laboratory testing
3.8.3.2 Increasing popularity of personalized medicine
Chapter 4 BY TECHNIQUES
4.1 Key growth factors and opportunities
4.2 Market size and forecast
4.3 Immunoassay/Immunochemistry
4.3.1 Key growth factors and opportunities
4.3.2 Market size and forecast
4.4 Clinical Chemistry
4.4.1 Key growth factors and opportunities
4.4.2 Market size and forecast
4.4.2.1 Urine chemistry analyzers
4.4.2.2 Blood gas electrolyte analyzers
4.5 Hematology
4.5.1 Key growth factors and opportunities
4.5.2 Market size and forecast
4.5.2.1 High throughput analyzers
4.5.2.2 Medium throughput analyzers
4.5.2.3 Low throughput analyzers
4.6 Coagulation
4.6.1 Key growth factors and opportunities
4.6.2 Market size and forecast
4.7 Point of care
4.7.1 Key growth factors and opportunities
4.7.2 Market size and forecast
4.8 Microbiology
4.8.1 Key growth factors and opportunities
4.8.2 Market size and forecast
4.8.2.1 Blood culture
4.8.2.2 Pathological culture
4.8.2.3 Identification & antibiotic susceptibility testing
4.8.2.4 Others
4.9 Molecular Diagnostics
4.9.1 Key growth factors and opportunities
4.9.2 Market size and forecast
4.9.3 Infectious diseases
4.9.4 Oncology
4.9.5 Genetic diseases
4.9.6 Blood Screening
4.9.7 Others
4.10 Whole Blood Glucose
4.10.1 Key growth factors and opportunities
4.10.2 Market size and forecast
4.11 Other Clinical Techniques
4.11.1 Key growth factors and opportunities
4.11.2 Market size and forecast
4.11.3 Clinical centrifuges
4.11.4 Tissue diagnosis
4.11.5 Sample processors
4.11.6 Flow cytometry
4.11.7 Cytology
Chapter 5 BY PRODUCT TYPE
5.1 Market size and forecast
5.2 Instruments
5.2.1 Key growth factors and opportunities
5.2.2 Market size and forecast
5.3 Reagents
5.3.1 Key growth factors and opportunities
5.3.2 Market size and forecast
5.4 Data management system hardware/software
5.4.1 Key growth factors and opportunities
5.4.2 Market size and forecast
5.5 Services
5.5.1 Key growth factors and opportunities
5.5.2 Market size and forecast
Chapter 6 BY USABILITY
6.1 Market size and forecast
6.2 Disposable IVD devices
6.2.1 Key growth factors and opportunities
6.2.2Market size and forecast
6.3 Re-usable IVD devices
6.3.1 Key growth factors and opportunities
6.3.1 Market size and forecast
Chapter 7 BY APPLICATION
7.1 Market size and forecast
7.2 Infectious diseases
7.2.1 Market size and forecast
7.3 Diabetes
7.3.1 Market size and forecast
7.4 Cancer/Oncology
7.4.1 Market size and forecast
7.5 Cardiology
7.5.1 Market size and forecast
7.6 Autoimmune diseases
7.6.1 Market size and forecast
7.7 Nephrology
7.7.1 Market size and forecast
7.8 Drug Testing
7.8.1 Market size and forecast
7.9 HIV/AIDS
7.9.1 Market size and forecast
7.10 Other Applications
7.10.1 Market size and forecast
Chapter 8 BY END-USERS
8.1 Market size and forecast
8.2 Hospitals
8.2.1 Market size and forecast
8.3 Laboratory
8.3.1 Market size and forecast
8.4 Academics
8.4.1 Market size and forecast
8.5 Point-of-Care /self-testing
8.5.1 Market size and forecast
8.6 Others
8.6.1 Market size and forecast
Chapter 9 BY COUNTRIES
9.1 Market size and forecast
9.2 India
9.2.1 Competitive Analysis
9.2.2 Key Growth Factors and Opportunities
9.2.3 Market size and forecast
9.3 China
9.3.1 Competitive Analysis
9.3.2 Key Growth Factors and Opportunities
9.3.3Market size and forecast
9.4 Japan
9.4.1 Competitive Analysis
9.4.2 Key Growth Factors and Opportunities
9.4.3 Market size and forecast
9.5 Australia
9.5.1 Competitive Analysis
9.5.2 Key Growth Factors and Opportunities
9.5.3 Market size and forecast
9.6 South Korea
9.6.1 Competitive Analysis
9.6.2 Key Growth Factors and Opportunities
9.6.3 Market size and forecast
9.7 Others
9.7.1 Competitive Analysis
9.7.2 Key Growth Factors and Opportunities
9.7.3 Market size and forecast
Chapter 10 COMPANY PROFILES
10.1 Danaher Corporation.
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Business performance
10.1.4 Key Strategies and development
10.1.5 SWOT analysis of Danaher
10.2 Vela Diagnostics
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Key Strategies and development
10.2.4 SWOT analysis of Vela Diagnostics
10.3 Affymetrix Inc.
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3Financial performance of Affymetrix Inc.
10.3.4Key Strategies and development
10.3.5SWOT analysis of Affymetrix
10.4 Alere Inc.
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Financial performance of Alere Inc.
10.4.4 Business performance
10.4.5 Key Strategies and developments
10.4.6 SWOT analysis of Alere
10.5 BioMerieux
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Financial performance of BioMerieux
10.5.4 Key Strategies and developments
10.5.5 SWOT analysis of BioMerieux
10.6 Roche Diagnostics.
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Financial performance of Roche Diagnostics
10.6.4 Key Strategies and developments
10.6.5 SWOT analysis of Roche Diagnostics
10.7 Becton, Dickinson And Company
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Financial Performance
10.7.4 Key Strategies and development
10.7.5 SWOT analysis of Becton Dickinson and Company
10.8 Bio-Rad Laboratories
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3Financial Performance
10.8.4Key Strategies and developments
10.8.5SWOT analysis of Bio-Rad Laboratories
10.9 Abbott Laboratories Inc.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Financial Performance
10.9.4 Key Strategies and developments
10.9.5 SWOT analysis of Abbott Laboratories
10.10 Transasia Bio-Medicals Ltd.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Business Operating Segments
10.10.4 Key Strategies and Development
10.10.5 SWOT analysis of Transasia Bio-Medicals Ltd.
10.11 Arkray Inc.
10.11.1 Company overview
10.11.2 Company snapshot
10.11.3 Key Strategies and development
10.11.4 SWOT analysis of Arkray Inc.
10.12 Sysmex Corporation
10.12.1 Company overview
10.12.2 Company snapshot
10.12.3 Business performance
10.12.4 Key strategies and developments
10.12.5 SWOT analysis of Sysmex
10.13 Johnson & Johnson
10.13.1 Company overview
10.13.2 Company snapshot
10.13.3 Business Performance
10.13.4 Key Strategies and Development
10.13.5 SWOT analysis of Johnson & Johnson
10.14 Siemens Healthcare
10.14.1 Company overview
10.14.2 Company snapshot
10.14.3 Business performance
10.14.4 Key Strategies and development
10.14.5 SWOT analysis of Siemens
List of figure
FIG. 1 IMPACT ANALYSIS OF ASIA PACIFIC IVD MARKET (2014-2020)
FIG. 2 POTENTIAL INVESTMENT POCKETS OF APAC IVD MARKET, BY TECHNOLOGY, 2014-2020
FIG. 3 KEY MARKET STRATEGIES IN IVD MARKET
FIG. 4 TOP WINNING STRATEGIES (2011-2015)
FIG. 5 VALUE CHAIN ANALYSIS FOR IVD MARKET
FIG. 6 PORTER`S FIVE FORCES MODEL OF ASIA PACIFIC IVD MARKET
FIG. 7 MARKET SHARE ANALYSIS OF ASIA-PACIFIC IVD MARKET (2014)
FIG. 8 ASIA PACIFIC KEY FACTS ON HIV IN 2013
FIG. 9 KEY FINANCIALS OF DANAHER SALES BY SEGMENT 2013
FIG. 10 KEY FINANCIALS OF DANAHER SALES BY GEOGRAPHY 2013
FIG. 11 SWOT ANALYSIS OF DANAHER
FIG. 12 SWOT ANALYSIS OF VELA DIAGNOSTICS
FIG. 13 KEY FINANCIALS OF AFFYMETRIX INC. REVENUE, 2011-2014, $MILLION
FIG. 14 KEY FINANCIALS OF AFFYMETRIX INC. REVENUE BY SEGMENTS
FIG. 15 KEY FINANCIALS OF AFFYMETRIX INC.CORPORATION REVENUE BY GEOGRAPHY
FIG. 16 SWOT ANALYSIS OF AFFYMETRIX INC.
FIG. 17 KEY FINANCIALS OF ALERE INC. REVENUE, 2011-2014, $MILLION
FIG. 18 KEY FINANCIALS OF ALERE INC.REVENUE BY SEGMENTS
FIG. 19 KEY FINANCIALS OF ALERE INC. REVENUE BY GEOGRAPHY
FIG. 20 SWOT ANALYSIS OF ALERE INC
FIG. 21 KEY FINANCIALS OF BIOMERIEUX REVENUE, 2011-2014, $MILLION
FIG. 22 KEY FINANCIALS OF BREAKDOWN OF SALES BY APPLICATION, 2013
FIG. 23 KEY FINANCIALS OF BREAKDOWN OF SALES BY GEOGRAPHY, 2013
FIG. 24 SWOT ANALYSIS OF BIOMERIEUX
FIG. 25 KEY FINANCIALS OF ROCHE DIAGNOSTICS REVENUE, 2011-2014, $MILLION
FIG. 26 KEY FINANCIALS OF ROCHE DIAGNOSTICS REVENUES BY SEGMENT, 2014
FIG. 27 KEY FINANCIALS OF ROCHE DIAGNOSTICS SALES BY GEOGRAPHY 2014
FIG. 28 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 29 KEY FINANCIALS OF BECTON, DICKINSON AND COMPANY REVENUE, 2011-2014, $MILLION
FIG. 30 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY REVENUES BY SEGMENT 2014
FIG. 31 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY SALES BY GEOGRAPHY 2014
FIG. 32 SWOT ANALYSIS OF BECTON,DICKINSON AND COMPANY
FIG. 33 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUE, 2011-2014, $MILLION
FIG. 34 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY SEGMENT 2013
FIG. 35 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY GEOGRAPHY 2013
FIG. 36 SWOT ANALYSIS OF BIO-RAD LABORATORIES
FIG. 37 KEY FINANCIALS OF ABBOTT LABORATORIES REVENUE, 2011-2014, $MILLION
FIG. 38 KEY FINANCIALS OF ABBOTT LABORATORIES INC REVENUES BY SEGMENT 2013
FIG. 39 KEY FINANCIALS OF ABBOTT LABORATORIES INC REVENUES BY GEOGRAPHY 2013
FIG. 40 SWOT ANALYSIS OF ABBOTT LABORATORIES
FIG. 41 COMPANY SNAPSHOT OF TRANSASIA BIOMEDICALS
FIG. 42 SWOT ANALYSIS OF TRANSASIA BIO-MEDICALS LTD
FIG. 43 SWOT ANALYSIS OF ARKRAY INC.
FIG. 44 KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY SEGMENT 2013
FIG. 45 KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY GEOGRAPHY 2013
FIG. 46 SWOT ANALYSIS OF SYSMEX
FIG. 47 KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY SEGMENT 2013
FIG. 48 KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY GEOGRAPHY 2013
FIG. 49 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 50 KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY SEGMENT 2013
FIG. 51 KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY GEOGRAPHY 2013
FIG. 52 SWOT ANALYSIS OF SIEMENS
List of tables:
TABLE 1 CLINICAL TRIALS - IN VITRO DIAGNOSTIC DEVICES
TABLE 2 GLOBAL INCIDENCES OF DISEASES (2011, 2012 & 2030)
TABLE 3 GOVERNMENT HEALTHCARE SPENDING IN ASIA PACIFIC COUNTRIES 2011
TABLE 4 COMPARISON OF ESTIMATED HEALTHCARE EXPENDITURE IN ASIA (1999, 2015, 2030) (US$ MILLION)
TABLE 5 ASIA PACIFIC IVD MARKET, BY TECHNIQUES, VALUE, 2014-2020, ($MILLION)
TABLE 6 ASIA PACIFIC IVD TECHNIQUES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 7 ASIA PACIFIC IVD IMMUNOASSAY/IMMUNOCHEMISTRY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 8 ASIA PACIFIC IVD CLINICAL CHEMISTRY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 9 ASIA PACIFIC IVD HEMATOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 10 ASIA PACIFIC IVD COAGULATION MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 11 ASIA PACIFIC IVD POINT-OF-CARE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 12 ASIA PACIFIC IVD MICROBIOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 13 ASIA PACIFIC IVD MOLECULAR DIAGNOSTICS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 14 ASIA PACIFIC IVD WHOLE BLOOD GLUCOSE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 15 ASIA PACIFIC IVD OTHER CLINICAL TECHNIQUES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 16 ASIA PACIFIC IVD MARKET, BY PRODUCT TYPE, VALUE, 2014-2020, ($MILLION)
TABLE 17 ASIA PACIFIC IVD , BY PRODUCT TYPE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 18 ASIA PACIFIC IVD INSTRUMENTS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 19 ASIA PACIFIC IVD REAGENTS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 20 ASIA PACIFIC IVD DATA MANAGEMENT SYSTEM HARDWARE/SOFTWARE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 21 ASIA PACIFIC IVD SERVICES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 22 ASIA PACIFIC IVD MARKET, BY USABILITY, VALUE, 2014-2020, ($MILLION)
TABLE 23 ASIA PACIFIC IVD , BY USABILITY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 24 ASIA PACIFIC DISPOSABLE IVD DEVICES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 25 LIST OF MANUFACTURERS WITH RE-USABLE IVD DEVICES
TABLE 26 ASIA PACIFIC RE-USABLE IVD DEVICES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 27 ASIA PACIFIC IVD MARKET, BY APPLICATION, VALUE, 2014-2020, ($MILLION)
TABLE 28 ASIA PACIFIC IVD , BY APPLICATION MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 29 ASIA PACIFIC IVD INFECTIOUS DISEASES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 30 ASIA PACIFIC IVD DIABETES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 31 ASIA PACIFIC IVD CANCER/ONCOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 32 ASIA PACIFIC IVD CARDIOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 33 ASIA PACIFIC IVD AUTOIMMUNE DISEASES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 34 ASIA PACIFIC IVD NEPHROLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 35 ASIA PACIFIC IVD DRUG TESTING MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 36 ASIA PACIFIC IVD HIV/AIDS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 37 INCIDENCE AND PREVALENCE OF DEMENTIA IN ASIA PACIFIC REGION (2005,2020 & 2050)
TABLE 38 ASIA PACIFIC IVD OTHER APPLICATION MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 39 ASIA PACIFIC IVD MARKET, BY END-USERS, VALUE, 2014-2020, ($MILLION)
TABLE 40 ASIA PACIFIC IVD , BY END-USERS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 41 ASIA PACIFIC HOSPITAL IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 42 ASIA PACIFIC LABORATORY IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 43 ASIA PACIFIC ACADEMICS IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 44 ASIA PACIFIC POINT-OF-CARE/SELF-TESTING IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 45 ASIA PACIFIC OTHER IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 46 ASIA-PACIFIC IVD MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)
TABLE 47 INDIA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)
TABLE 48 REGULATORY SUMMARY FOR IVD DEVICES IN CHINA
TABLE 49 CHINA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)
TABLE 50 JAPAN IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)
TABLE 51 CATEGORIZATION OF IVD DEVICES
TABLE 52 AUSTRALIA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)
TABLE 53 SOUTH KOREA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)
TABLE 54 OTHER APAC REGION IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)
TABLE 55 DANAHER COMPANY SNAPSHOT
TABLE 56 VELA DIAGNOSTICS COMPANY SNAPSHOT
TABLE 57 COMPANY SNAPSHOT AFFYMETRIX INC.
TABLE 58 COMPANY SNAPSHOT ALERE INC
TABLE 59 BIOMERIEUX COMPANY SNAPSHOT
TABLE 60 COMPANY SNAPSHOT OF ROCHE DIAGNOSTICS
TABLE 61 COMPANY SNAPSHOT OF BECTON, DICKINSON AND COMPANY
TABLE 62 SNAPSHOT OF BIO-RAD LABORATORIES
TABLE 63 SNAPSHOT OF ABBOTT LABORATORIES INC
TABLE 64 TRANSASIA BIOMEDICALS OPERATING BUSINESS SEGMENTS
TABLE 65 COMPANY SNAPSHOT OF ARKRAY INC
TABLE 66 COMPANY SNAPSHOT OF SYSMEX CORPORATION
TABLE 67 JOHNSON & JOHNSON COMPANY SNAPSHOT
TABLE 68 SIEMENS COMPANY SNAPSHOT
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : November 2019
$ 3600
Published On : November 2019
$ 3600
Published On : November 2019
$ 3600
$ 3950
Published On : April 2019
$ 3000
